Sandoz Group AG

SDZNY | OTC

Price Alert Chart Builder DCF Calculator

$101.69

+$0.48 (+0.47%)

At close: Nov 5, 2026, 3:59 PM ET

$101.36

-$0.33 (-0.32%)

After-hours: Nov 5, 2026, 3:58 PM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+0.47%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

44.7

+0.3 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #395/1024 (Top 39%)

Full Analysis

Key Statistics

Market Data

Market Cap $44B

1D Range

101.17 102.49

52W Range

65.90 102.49

Valuation (TTM)

PE 67.93

PB 4.85

EV/EBITDA 20.82

Valuation (NTM)

Forward PE 21.81

Forward PEG 2.81

Price Target $0.00

Cash Flow

FCF Yield 2.5%

SBC Adj. FCF Yield 2.2%

SBC Impact -9.4%

Margins

Gross Margin 47.5%

Operating Margin 15.8%

FCF Margin 9.4%

Growth (CAGR)

Revenue 3Y | 5Y 39.2% | 3.1%

Dil EPS 3Y | 5Y 46.9% | 17.1%

FCF 3Y | 5Y 44.3% | 2.4%

Returns

ROA 2.8%

ROE 7.0%

ROIC 8.8%

Financial Health

Net Debt

$4.68B

Current Ratio 1.05

Interest Coverage 8.45

Dividends

Div Yield 1.01%

Payout Ratio 68.5%

FCF Payout Ratio 40.2%

All Key Statistics

Loading financial charts...

Profile

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious dise...

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Employees 23,000

IPO Date Oct 4, 2023

Website www.sandoz.com

Fiscal Year n/a

Full Company Profile

Latest News

1 day ago · zacks.com

COLL or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a better bang for their buck right now?

9 days ago · seekingalpha.com

Sandoz Group AG (SDZNY) Q3 2026 Sales/Trading Call Transcript

9 days ago · wsj.com

Sandoz Shares Fall After Company Turns Cautious on Sales Guidance

Shares dropped after the company issued a more cautious outlook on top-line growth for 2026, citing challenging conditions in Germany and supply constraints for biosimilar drugs.

9 days ago · reuters.com

Generic drugmaker Sandoz lowers sales outlook, lifts profit forecast

Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on

23 days ago · zacks.com

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?

1 month ago · zacks.com

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?

2 months ago · prnewswire.com

mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.

2 months ago · wsj.com

Sandoz Gets Canada Approval for Generic Version of Ozempic

The approval for its generic version of diabetes drug Ozempic advances its efforts to build a portfolio of GLP-1 medicines.

2 months ago · seekingalpha.com

Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript

2 months ago · zacks.com

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?